Knowledge on rare diseases and orphan drugs
COVID-19 & Rare diseases
Rare Diseases Resources for Refugees/Displaced Persons
Search for a rare disease
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome
An intermediate form of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum characterized by destruction and detachment of the skin epithelium, involving between 10 to 29% of the body surface area, and mucous membranes. Onset usually occurs 4-28 days after administration of the causal medication and is most frequently associated with anticonvulsants, antibacterial sulfonamides, allopurinol, nevirapine, and oxicams (non-steroidal anti-inflammatory drugs), but many other medications have also been implicated. The disease is not induced by medication in 15% of cases. Histology is characterized by an epidermal necrolysis. Multiple disabling long-term sequelae (especially cutaneous, ocular and psychological) are frequent.
ORPHA:506784
: produced/endorsed by ERN(s)
: produced/endorsed by FSMR(s)
Guidelines
Disease review articles
Further information on this disease
Patient-centred resources for this disease
Research activities on this disease
- Research project(s) (28)
- Clinical trial(s) (1)
- Biobank(s) (3)
- Registry(ies) (22)
- Network of experts (2)
Newborn screening